Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs...
Gespeichert in:
| Veröffentlicht in: | Frontiers in pharmacology Jg. 12; S. 625296 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Frontiers Media S.A
25.06.2021
|
| Schlagworte: | |
| ISSN: | 1663-9812, 1663-9812 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Introduction:
Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany.
Methods:
Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios.
Results:
Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules.
Conclusion:
Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact. |
|---|---|
| AbstractList | Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany.
Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios.
Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules.
Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact. Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany.Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios.Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules.Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact. Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany. Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios. Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules. Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact.Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany. Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios. Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules. Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact. Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by European countries to design the biologicals market and explores potential savings from the increased use of biosimilar medicines in Germany. Methods: Policy measures that target the price and uptake of biosimilar medicines were identified based on a prefilled questionnaire survey with public authorities in 16 European countries, who were the members of the Pharmaceutical Pricing and Reimbursement Information network (July 2020). Potential savings that could have been generated in Germany if different measures identified in the surveyed countries had been implemented were calculated for six publicly funded biological molecules. Price data of the Pharma Price Information service and German consumption data for 2018 were used for the calculation of five scenarios. Results: Several countries use a price link policy, setting the biosimilar price as a percentage of the price of the reference biological. Also lowering the price of the reference biological upon market entry of a biosimilar is less frequently used. While tendering of biosimilar medicines in the inpatient setting is the norm, it is rarely employed for biosimilars in outpatient use. Reference price systems and INN prescribing of medicines are the commonly used policy measures in the off-patent market, but some countries define exemptions for biologicals. Substituting biosimilars at the pharmacy level is rather an exception. Potential savings in Germany ranged from 5% (simple price link) to 55% (prices at the level of other countries) for the six studied molecules. Conclusion: Despite some differences, there are discernible tendencies across European countries with regard to their applications of certain policy measures targeting the price and uptake of biosimilar medicines. The potential for savings of some of these policies was clearly demonstrated. Monitoring and evaluation of these rather recent measures is key for obtaining a more comprehensive picture of their impact. |
| Author | Vogler, Sabine Panteli, Dimitra Schneider, Peter Zuba, Martin Busse, Reinhard |
| AuthorAffiliation | 2 Department of Health Economics and Health Systems Analysis, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna , Austria 3 Department of Health Care Management, Technische Universität Berlin, Berlin , Germany 1 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna , Austria |
| AuthorAffiliation_xml | – name: 3 Department of Health Care Management, Technische Universität Berlin, Berlin , Germany – name: 2 Department of Health Economics and Health Systems Analysis, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna , Austria – name: 1 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute (Gesundheit Österreich GmbH/GÖG), Vienna , Austria |
| Author_xml | – sequence: 1 givenname: Sabine surname: Vogler fullname: Vogler, Sabine – sequence: 2 givenname: Peter surname: Schneider fullname: Schneider, Peter – sequence: 3 givenname: Martin surname: Zuba fullname: Zuba, Martin – sequence: 4 givenname: Reinhard surname: Busse fullname: Busse, Reinhard – sequence: 5 givenname: Dimitra surname: Panteli fullname: Panteli, Dimitra |
| BookMark | eNp9Uk1v1DAQjVARLaU_gJuPXHaJP-LYFyRYLe1KldhDe7Yce7LrKrGD7aAi_jxOt0KUA3OZ0cy8N2-k97Y688FDVb3H9ZpSIT_201HHNakJXnPSEMlfVReYc7qSApOzv-rz6iqlh7oElZJy9qY6p4wwwXFzUf3ah8EZBwnlgLbehDnqA6B8BHSfAIUefXEhudENOibkPNrOMUygPdqE2ee4ILW36O4ILqJ9yOCz0wPajZM2GQWP9kXmqA3M2Zky2D5O4K3Lc4R31eteDwmunvNldf91e7e5Wd1-u95tPt-uDGMkr7qaddx2osVS8lI1wna66WjNqeiJkK2ue2lNw_taMlayJVAadYs5s61p6GW1O_HaoB_UFN2o408VtFNPjRAPSseibgBleVNL3nILomVEcE16STTgvlzvG9YWrk8nrmnuRrCmvBv18IL05cS7ozqEH0oQ3jK8iPnwTBDD9xlSVqNLBoZBewhzUqRpymOUU1ZW8WnVxJBShP7PGVyrxQPqyQNq8YA6eaBg2n8wxmWdXVjUuOE_yN8-1LoY |
| CitedBy_id | crossref_primary_10_1111_1756_185X_70140 crossref_primary_10_3389_fphar_2021_795002 crossref_primary_10_1186_s40545_023_00581_w crossref_primary_10_1016_j_yrtph_2023_105485 crossref_primary_10_3389_fphar_2023_1188368 crossref_primary_10_3390_pharmacy13030085 crossref_primary_10_1007_s40259_024_00652_7 crossref_primary_10_1007_s40258_022_00751_y crossref_primary_10_1111_nyas_15171 crossref_primary_10_1007_s12325_023_02766_w crossref_primary_10_1016_j_sapharm_2022_03_009 crossref_primary_10_1001_jamanetworkopen_2023_15872 crossref_primary_10_1111_jcpt_13783 crossref_primary_10_1080_14712598_2022_2012146 crossref_primary_10_1080_14712598_2024_2307353 crossref_primary_10_1007_s40259_023_00640_3 crossref_primary_10_1016_j_vhri_2025_101142 crossref_primary_10_3389_fphar_2022_917814 crossref_primary_10_3389_fphar_2023_1256542 crossref_primary_10_3389_fphar_2023_1151764 crossref_primary_10_1080_14737167_2023_2146579 crossref_primary_10_1080_14712598_2025_2508838 crossref_primary_10_1002_acr_25099 crossref_primary_10_3390_antibiotics11080987 crossref_primary_10_3390_ph17070925 crossref_primary_10_1080_13696998_2025_2558450 crossref_primary_10_1186_s12961_023_01015_4 crossref_primary_10_1186_s12913_025_13017_9 crossref_primary_10_1080_14712598_2023_2189008 crossref_primary_10_3390_healthcare10081594 crossref_primary_10_1007_s40259_025_00721_5 crossref_primary_10_1136_bmjopen_2024_090484 crossref_primary_10_1001_jamanetworkopen_2022_44670 crossref_primary_10_3390_biologics3020006 crossref_primary_10_1111_dom_70082 crossref_primary_10_1007_s10792_023_02853_5 crossref_primary_10_1016_j_zefq_2022_09_009 crossref_primary_10_1007_s40259_024_00659_0 crossref_primary_10_1093_bjd_ljae454 crossref_primary_10_1007_s40259_023_00636_z crossref_primary_10_1186_s40545_022_00451_x crossref_primary_10_1007_s40259_025_00710_8 crossref_primary_10_3389_fpubh_2025_1533710 crossref_primary_10_1111_dom_16110 crossref_primary_10_1007_s43441_024_00623_8 crossref_primary_10_1080_14712598_2022_2076557 crossref_primary_10_1001_jamadermatol_2025_0055 crossref_primary_10_1007_s40259_025_00727_z crossref_primary_10_1080_14712598_2022_2070428 crossref_primary_10_1007_s40259_025_00709_1 crossref_primary_10_1093_bjd_ljad107 crossref_primary_10_1007_s43441_022_00473_2 crossref_primary_10_3390_pharmaceutics14091766 crossref_primary_10_1155_2022_8080308 crossref_primary_10_1016_j_hpopen_2024_100129 crossref_primary_10_1371_journal_pone_0312577 crossref_primary_10_3389_fpubh_2024_1263472 |
| Cites_doi | 10.1007/s12325-017-0522-y 10.1016/S0140-6736(17)30068-5 10.5639/gabij.2012.0103-4.036 10.1371/journal.pone.0190147 10.1016/j.glohj.2019.11.005 10.1016/j.hlpt.2014.01.001 10.1007/s12325-015-0233-1 10.1016/j.jval.2013.08.2291 10.1586/14737167.2015.1067142 10.3389/fphar.2017.00288 10.3389/fphar.2017.00171 10.1016/j.healthpol.2014.02.011 10.1007/s40264-019-00845-y 10.1016/j.healthpol.2011.03.004 10.3109/00365521.2015.1054422 10.24945/mvf.06.18.1866-0533.2103 10.1007/978-3-662-54630-7_7 10.1002/acr.24012 10.3389/fphar.2018.01070 10.1111/jphs.12180 10.5639/gabij.2015.0402.018 10.1136/annrheumdis-2017-211937 10.3389/fphar.2016.00197 10.1007/s40273-015-0380-x 10.3389/fphar.2020.00970 10.1007/s40259-017-0252-3 10.18553/jmcp.2019.25.1.102 10.1111/imj.14753 10.1007/s10198-013-0538-4 10.1007/s40259-020-00461-8 10.1007/s10198-014-0595-3 10.3389/fphar.2017.00322 10.3389/fphar.2019.01375 10.1136/bmj.l5444 10.3389/fpubh.2018.00328 10.1136/bmjopen-2019-034183 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Vogler, Schneider, Zuba, Busse and Panteli. Copyright © 2021 Vogler, Schneider, Zuba, Busse and Panteli. 2021 Vogler, Schneider, Zuba, Busse and Panteli |
| Copyright_xml | – notice: Copyright © 2021 Vogler, Schneider, Zuba, Busse and Panteli. – notice: Copyright © 2021 Vogler, Schneider, Zuba, Busse and Panteli. 2021 Vogler, Schneider, Zuba, Busse and Panteli |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fphar.2021.625296 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals - NZ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Vogler et al |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_d6509676de874286a2f92ae1f871f547 PMC8267415 10_3389_fphar_2021_625296 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c442t-b04b6db871996b6d58dba5b30638f2897a0f9dc56f0944c56d2ef9d07164d7c53 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 60 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000670891300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1663-9812 |
| IngestDate | Fri Oct 03 12:45:08 EDT 2025 Tue Sep 30 16:42:38 EDT 2025 Wed Oct 01 13:49:07 EDT 2025 Tue Nov 18 21:04:31 EST 2025 Sat Nov 29 05:30:36 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-b04b6db871996b6d58dba5b30638f2897a0f9dc56f0944c56d2ef9d07164d7c53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology Edited by: Maria Dimitrova, Medical University Sofia, Bulgaria Antoaneta Tsvetkova, Medical University of Varna, Bulgaria Reviewed by: João Eurico Fonseca, University of Lisbon, Portugal Márta Péntek, Óbuda University, Hungary |
| OpenAccessLink | https://doaj.org/article/d6509676de874286a2f92ae1f871f547 |
| PMID | 34248615 |
| PQID | 2550633634 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d6509676de874286a2f92ae1f871f547 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8267415 proquest_miscellaneous_2550633634 crossref_primary_10_3389_fphar_2021_625296 crossref_citationtrail_10_3389_fphar_2021_625296 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-06-25 |
| PublicationDateYYYYMMDD | 2021-06-25 |
| PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in pharmacology |
| PublicationYear | 2021 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | B21 B23 B25 B28 Kawalec (B33) 2017; 8 Brodszky (B10) 2014; 15 (B61) 2016 (B62) 2020 Farfan-Portet (B19) 2014; 15 Busse (B13) 2017 Gulácsi (B26) 2017; 34 Kay (B34) 2018; 77 Ferrario (B20) 2020; 368 Moorkens (B44) 2017; 12 Schneider (B53) 2018 Curto (B14) 2014; 116 Jang (B29) 2021; 35 Abbott (B1) 2019; 3 Luley (B38) 2018; 11 B4 B5 B6 Belleudi (B9) 2019; 42 Baji (B8) 2016; 51 Jha (B30) 2015; 32 B42 Vogler (B60) 2019 B43 Kanters (B32) 2017; 8 B45 Troein (B56) 2019 B46 B47 Aladul (B3) 2017; 31 Haustein (B27) 2012; 1 Brodszky (B11) 2016; 16 Kovitwanichkanont (B36) 2020; 50 Sarnola (B52) 2020; 10 Vogler (B58) 2014; 3 Vogler (B59) 2017; 8 Dylst (B16) 2011; 101 (B2) 2017 Babar (B7) 2019; 10 Gasteiger (B22) 2020; 72 B50 Mestre-Ferrandiz (B41) 2016; 34 B51 de Bruijn (B15) 2016; 7 Kim (B35) 2020; 11 Leonard (B37) 2019; 25 B12 B57 B17 B18 Godman (B24) 2018; 6 Jørgensen (B31) 2017; 389 Sullivan (B54) 2014; 17 Manova (B40) 2018; 9 Panteli (B48) 2016; 18 Pauwels (B49) 2017; 8 (B55) 2020 Mack (B39) 2015; 4 |
| References_xml | – ident: B12 – volume: 34 start-page: 1128 year: 2017 ident: B26 article-title: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries publication-title: Adv. Ther. doi: 10.1007/s12325-017-0522-y – volume: 389 start-page: 2304 year: 2017 ident: B31 article-title: Switching from Originator Infliximab to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab (NOR-SWITCH): a 52-week, Randomised, Double-Blind, Non-inferiority Trial publication-title: Lancet doi: 10.1016/S0140-6736(17)30068-5 – volume: 1 start-page: 120 year: 2012 ident: B27 article-title: Saving Money in the European Healthcare Systems with Biosimilars publication-title: Gabi J. doi: 10.5639/gabij.2012.0103-4.036 – volume: 12 start-page: e190147 year: 2017 ident: B44 article-title: Policies for Biosimilar Uptake in Europe: an Overview publication-title: PLoS One doi: 10.1371/journal.pone.0190147 – volume-title: PPRI Report 2018 year: 2019 ident: B60 – volume: 3 start-page: 79 year: 2019 ident: B1 article-title: Policy Options for Addressing the High Cost of Specialty Pharmaceuticals publication-title: Glob. Health J. doi: 10.1016/j.glohj.2019.11.005 – volume: 3 start-page: 139 year: 2014 ident: B58 article-title: The Pharmaceutical Pricing and Reimbursement Information (PPRI) Initiative-Experiences from Engaging with Pharmaceutical Policy Makers publication-title: Health Pol. Tech. doi: 10.1016/j.hlpt.2014.01.001 – ident: B45 – volume: 32 start-page: 742 year: 2015 ident: B30 article-title: The Budget Impact of Biosimilar Infliximab (Remsima) for the Treatment of Autoimmune Diseases in Five European Countries publication-title: Adv. Ther. doi: 10.1007/s12325-015-0233-1 – volume: 17 start-page: 5 year: 2014 ident: B54 article-title: Budget Impact Analysis-Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force publication-title: Value in Health doi: 10.1016/j.jval.2013.08.2291 – ident: B25 – ident: B50 – ident: B21 – volume: 16 start-page: 119 year: 2016 ident: B11 article-title: A Budget Impact Model for Biosimilar Infliximab in Crohn's Disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia publication-title: Expert Rev. Pharmacoecon Outcomes Res. doi: 10.1586/14737167.2015.1067142 – volume: 8 start-page: 288 year: 2017 ident: B33 article-title: Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00288 – volume: 8 start-page: 171 year: 2017 ident: B49 article-title: Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00171 – volume: 116 start-page: 182 year: 2014 ident: B14 article-title: Regional Tenders on Biosimilars in Italy: an Empirical Analysis of Awarded Prices publication-title: Health Policy doi: 10.1016/j.healthpol.2014.02.011 – volume: 42 start-page: 1437 year: 2019 ident: B9 article-title: Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study publication-title: Drug Saf. doi: 10.1007/s40264-019-00845-y – volume-title: Challenges and Opportunities in Improving Access to Medicines through Efficient Public Procurement in the WHO European Region year: 2016 ident: B61 – volume: 101 start-page: 146 year: 2011 ident: B16 article-title: Tendering for Outpatient Prescription Pharmaceuticals: what Can Be Learned from Current Practices in Europe? publication-title: Health Policy doi: 10.1016/j.healthpol.2011.03.004 – volume: 51 start-page: 22 year: 2016 ident: B8 article-title: Treatment Preferences of Originator versus Biosimilar Drugs in Crohn's Disease; Discrete Choice experiment Among Gastroenterologists publication-title: Scand. J. Gastroenterol. doi: 10.3109/00365521.2015.1054422 – ident: B28 – volume: 11 start-page: 10 year: 2018 ident: B38 article-title: Biologika: Steuern Selektivverträge die Verordnung? publication-title: MvF doi: 10.24945/mvf.06.18.1866-0533.2103 – ident: B6 – start-page: 195 volume-title: Arzneiverordnungs-Report 2017: Aktuelle Daten, Kosten, Trends and Kommentare year: 2017 ident: B13 article-title: Europäischer Preisvergleich für patentgeschützte Arzneimittel doi: 10.1007/978-3-662-54630-7_7 – ident: B17 – volume: 72 start-page: 1323 year: 2020 ident: B22 article-title: Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch publication-title: Arthritis Care Res. doi: 10.1002/acr.24012 – volume: 9 start-page: 1070 year: 2018 ident: B40 article-title: Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis publication-title: Front. Pharmacol. doi: 10.3389/fphar.2018.01070 – ident: B51 – volume: 8 start-page: 147 year: 2017 ident: B59 article-title: Tendering for Off-Patent Outpatient Medicines: Lessons Learned from Experiences in Belgium, Denmark and the Netherlands publication-title: J. Pharm. Health Serv. Res. doi: 10.1111/jphs.12180 – volume: 4 start-page: 90 year: 2015 ident: B39 article-title: Norway, Biosimilars in Different Funding Systems. What Works? publication-title: Gabi J. doi: 10.5639/gabij.2015.0402.018 – volume: 77 start-page: 165 year: 2018 ident: B34 article-title: Consensus-based Recommendations for the Use of Biosimilars to Treat Rheumatological Diseases publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2017-211937 – ident: B43 – volume: 7 start-page: 197 year: 2016 ident: B15 article-title: Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future publication-title: Front. Pharmacol. doi: 10.3389/fphar.2016.00197 – volume: 34 start-page: 609 year: 2016 ident: B41 article-title: Biosimilars: How Can Payers Get Long-Term Savings? publication-title: PharmacoEconomics doi: 10.1007/s40273-015-0380-x – ident: B5 – ident: B47 – volume-title: The Impact of Biosimilar Competition in Europe, October 2019 year: 2019 ident: B56 – ident: B23 – volume: 11 start-page: 970 year: 2020 ident: B35 article-title: Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion across Countries? publication-title: Front. Pharmacol. doi: 10.3389/fphar.2020.00970 – volume-title: WHO Guideline on Country Pharmaceutical Pricing Policies year: 2020 ident: B62 – ident: B18 – volume: 18 start-page: 1 year: 2016 ident: B48 article-title: Pharmaceutical Regulation in 15 European Countries Review publication-title: Health Syst. Transit. – volume: 31 start-page: 533 year: 2017 ident: B3 article-title: Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK publication-title: BioDrugs doi: 10.1007/s40259-017-0252-3 – volume: 25 start-page: 102 year: 2019 ident: B37 article-title: Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review publication-title: J. Manag. Care Spec. Pharm. doi: 10.18553/jmcp.2019.25.1.102 – volume-title: Preisvergleich Ausgabenstarker Arzneispezialitäten 2017 year: 2018 ident: B53 – volume: 50 start-page: 374 year: 2020 ident: B36 article-title: Who Is Afraid of Biosimilars? Openness to Biosimilars in an Australian Cohort of Patients with Rheumatoid Arthritis publication-title: Intern. Med. J. doi: 10.1111/imj.14753 – volume: 15 start-page: 223 year: 2014 ident: B19 article-title: Are Biosimilars the Next Tool to Guarantee Cost-Containment for Pharmaceutical Expenditures? publication-title: Eur. J. Health Econ. doi: 10.1007/s10198-013-0538-4 – ident: B42 – volume-title: International price Comparison 2019. An Analysis of Swedish Pharmaceutical Prices and Volumes Relative to 19 Other European Countries year: 2020 ident: B55 – volume: 35 start-page: 89 year: 2021 ident: B29 article-title: Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets publication-title: BioDrugs doi: 10.1007/s40259-020-00461-8 – volume: 15 start-page: S65 year: 2014 ident: B10 article-title: Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries publication-title: Eur. J. Health Econ. doi: 10.1007/s10198-014-0595-3 – ident: B4 – ident: B46 – volume: 8 start-page: 322 year: 2017 ident: B32 article-title: Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00322 – volume: 10 start-page: 1375 year: 2019 ident: B7 article-title: The Availability, Pricing and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-And High-Income Countries publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.01375 – volume: 368 start-page: l5444 year: 2020 ident: B20 article-title: Strategies to Achieve Fairer Prices for Generic and Biosimilar Medicines publication-title: BMJ doi: 10.1136/bmj.l5444 – volume-title: Handbuch Biosimilars year: 2017 ident: B2 – ident: B57 – volume: 6 start-page: 328 year: 2018 ident: B24 article-title: Barriers for Access to New Medicines: Searching for the Balance between Rising Costs and Limited Budgets publication-title: Front. Public Health doi: 10.3389/fpubh.2018.00328 – volume: 10 start-page: e034183 year: 2020 ident: B52 article-title: Physicians' Perceptions of the Uptake of Biosimilars: a Systematic Review publication-title: BMJ Open doi: 10.1136/bmjopen-2019-034183 |
| SSID | ssj0000399364 |
| Score | 2.4924614 |
| Snippet | Introduction:
Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from... Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 625296 |
| SubjectTerms | biological biosimilar cross-country comparison Pharmacology policy measure savings substitution |
| Title | Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure |
| URI | https://www.proquest.com/docview/2550633634 https://pubmed.ncbi.nlm.nih.gov/PMC8267415 https://doaj.org/article/d6509676de874286a2f92ae1f871f547 |
| Volume | 12 |
| WOSCitedRecordID | wos000670891300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals - NZ customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZt6KGX0ifdNg0qlBxK3DiyLFvHpmxIoQ17SGBvQk9iaOSw9hZCob89M7I3WV_aSy62sWRL1oyk-SzNN4R8qrXGMEgc-rcsMxj9qkzWxmS5NTw4xywzyVH4R3V2Vi-XcrEV6gv3hA30wEPDHTqkeBOVcL4GFFcLzYJk2h8FsPRDyZMfeV7JLTCVxmCcdwUfljEBhcnDcH2pkf-THX0Bk58hSf_WRJT4-idG5nSL5Nacc_KcPBuNRfp1qOQL8sjHl2R_MbBN3xzQ83vnqe6A7tPFPQ_1zSvyJ3H-AhKmfUvn0cLbYPCgYPHRi87TNtDjpu2aqwbBLW0i3fyZp-iojoG2Oqqjw1KaFV20PW4sgup8T46VtI2b8sYf4hRpk3EFfL3yr8nFyfz822k2xlrILOesz0zOjXAGGhUAEFyVtTO6NAVaNAFAWaXzIJ0tRQA8yOHsmIcbOcItV9myeEN2Yhv9W0JB-HmAgdQ6DmlM6tzUxhfBCC2NKNyM5JuGV3YkIsd4GL8UABKUlUqyUigrNchqRj7fPXI9sHD8K_MxSvMuIxJopxugVmpUK_U_tZqRjxtdUNDhcBVFR9-uOwUYDBqlEAWfkWqiJJMSpymxuUzU3QDm0IR79xBVfE-e4lfjvjVW7pKdfrX2H8gT-7tvutUeeVwt673UK-D48-_8FmeOFVA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Policies+to+Encourage+the+Use+of+Biosimilars+in+European+Countries+and+Their+Potential+Impact+on+Pharmaceutical+Expenditure&rft.jtitle=Frontiers+in+pharmacology&rft.au=Vogler%2C+Sabine&rft.au=Schneider%2C+Peter&rft.au=Zuba%2C+Martin&rft.au=Busse%2C+Reinhard&rft.date=2021-06-25&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=12&rft_id=info:doi/10.3389%2Ffphar.2021.625296&rft_id=info%3Apmid%2F34248615&rft.externalDocID=PMC8267415 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |